See also this year's filing and all EDGAR filings for this company.
PDF Report 0001034842_2012_Rigel_Pharmaceuticals_INC.pdf
Logs
| warning | NetIncome node detected by IncomeLoss name heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {} |
Graph
Absolute values for 0001034842, Rigel Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 250,233,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 4,882,000 |
| 3 | remainder_Assets | 1,991,000 |
| 4 | LiabilitiesCurrent | 11,527,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 21,768,000 |
| 9 | ResearchAndDevelopmentExpense | 69,350,000 |
| 10 | remainder_Expenses | 25,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 5,170,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 257,106,000 |
| 1 | Liabilities | 11,527,000 |
| 2 | Expenses | 91,143,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 245,579,000 |
| 5 | NetIncome | -85,973,000 |
| 6 | ComprehensiveNetIncome | -85,973,000 |
| 7 | BaseVar | 182,473,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.35 |
| 9 | EconomicCapitalRatio | 3.92 |
Edgar->Model Mapping
Feature Distribution
